

Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis

PLoS Medicine

9, e1001316

DOI: [10.1371/journal.pmed.1001316](https://doi.org/10.1371/journal.pmed.1001316)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Short-course amphotericin is cost-effective for cryptococcal meningitis. Springer Healthcare News, 2012, 1, 1.	0.0	0
2	Long Term 5-Year Survival of Persons with Cryptococcal Meningitis or Asymptomatic Subclinical Antigenemia in Uganda. PLoS ONE, 2012, 7, e51291.	2.5	55
3	Disseminated Pulmonary Cryptococcosis Complicated with Cryptococemia in an AIDS Patient. Journal of Experimental and Clinical Medicine, 2013, 5, 239-240.	0.2	2
4	3-Bromopyruvate: A novel antifungal agent against the human pathogen <i>Cryptococcus neoformans</i> . Biochemical and Biophysical Research Communications, 2013, 434, 322-327.	2.1	26
5	Cryptococcal Infections: Changing Epidemiology and Implications for Therapy. Drugs, 2013, 73, 495-504.	10.9	50
6	Cost-Effective Diagnostic Checklists for Meningitis in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e101-e108.	2.1	91
7	New Insights into HIV/AIDS-Associated Cryptococcosis. Isrn Aids, 2013, 2013, 1-22.	2.5	75
8	Cryptococcal meningitis: epidemiology and therapeutic options. Clinical Epidemiology, 2014, 6, 169.	3.0	207
9	Performance of Cryptococcal Antigen Lateral Flow Assay Using Saliva in Ugandans with CD4 ≤ 100. PLoS ONE, 2014, 9, e103156.	2.5	22
10	Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings. Open Forum Infectious Diseases, 2014, 1, ofu070.	0.9	36
11	Methods of rapid diagnosis for the etiology of meningitis in adults. Biomarkers in Medicine, 2014, 8, 1085-1103.	1.4	81
12	Synthetically modified l-histidine-rich peptidomimetics exhibit potent activity against <i>Cryptococcus neoformans</i> . Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3150-3154.	2.2	13
13	Accuracy of Noninvasive Intraocular Pressure or Optic Nerve Sheath Diameter Measurements for Predicting Elevated Intracranial Pressure in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2014, 1, ofu093.	0.9	34
14	Therapy of AIDS-Related Cryptococcal Meningitis. Current Treatment Options in Infectious Diseases, 2014, 6, 294-308.	1.9	2
15	Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. PLoS ONE, 2015, 10, e0142550.	2.5	9
16	Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis. Journal of Tropical Medicine, 2015, 2015, 1-6.	1.7	11
17	Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 2015, 33, A240-A247.	3.8	27
18	Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. American Journal of Tropical Medicine and Hygiene, 2015, 92, 274-279.	1.4	60

#	ARTICLE	IF	CITATIONS
19	Comparative Effectiveness of Induction Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: A Network Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv010.	0.9	7
20	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv046.	0.9	68
21	Cryptococcal Meningitis: Diagnosis and Management Update. <i>Current Tropical Medicine Reports</i> , 2015, 2, 90-99.	3.7	123
22	Host immunity to <i>Cryptococcus neoformans</i> . <i>Future Microbiology</i> , 2015, 10, 565-581.	2.0	102
23	Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. <i>Current Tropical Medicine Reports</i> , 2015, 2, 81-89.	3.7	38
24	Increased Antifungal Drug Resistance in Clinical Isolates of <i>Cryptococcus neoformans</i> in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7197-7204.	3.2	151
25	Low Prevalence of Cryptococcal Antigenemia among Patients Infected with HIV/AIDS in Haiti. <i>Journal of AIDS & Clinical Research</i> , 2016, 7, .	0.5	1
26	Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016, 371, 20150468.	4.0	88
27	Voriconazole combined with low-dose amphotericin B liposome for treatment of cryptococcal meningitis. <i>Infectious Diseases</i> , 2016, 48, 563-565.	2.8	11
28	Spectrum of neuroimaging findings in cryptococcal meningitis in immunocompetent patients in China—a series of 18 cases. <i>Journal of the Neurological Sciences</i> , 2016, 368, 132-137.	0.6	30
29	Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 120-131.	3.4	3
30	HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 92-102.	3.4	21
31	Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of <i>Cryptococcus neoformans</i> in macrophages. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 69-77.	2.5	20
32	Evaluation of antifungal combination against <i>Cryptococcus</i> spp.. <i>Mycoses</i> , 2016, 59, 585-593.	4.0	12
33	Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1564-1568.	5.8	43
34	Curcumin enhances the activity of fluconazole against <i>Cryptococcus gattii</i> -induced cryptococcosis infection in mice. <i>Journal of Applied Microbiology</i> , 2016, 120, 41-48.	3.1	23
35	Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis. <i>Medical Mycology</i> , 2016, 54, 361-369.	0.7	38
36	Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution. <i>International Journal of STD and AIDS</i> , 2016, 27, 110-117.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 331-340.	4.4	13
38	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 873-881.	9.1	1,559
39	<i>Cryptococcus</i> and <i>Cryptococcosis</i> . , 2017, , 169-214.		2
40	Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)â€“Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. <i>Clinical Infectious Diseases</i> , 2017, 65, 2126-2129.	5.8	54
41	Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 225.	2.9	25
42	Evaluation and management of the swollen opticâ€“disk in cryptococcal meningitis. <i>Survey of Ophthalmology</i> , 2017, 62, 150-160.	4.0	11
43	HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for â€œPrevention Is Better Than Cureâ€“. <i>Journal of Fungi</i> (Basel, Switzerland), 2017, 3, 67.	3.5	33
44	Efficacy of Prosopilosidine from <i>Prosopis glandulosa</i> var. <i>glandulosa</i> against <i>Cryptococcus neoformans</i> Infection in a Murine Model. <i>Molecules</i> , 2018, 23, 1674.	3.8	3
45	Safety and tolerability of intrathecal liposomal amphotericin <i>B</i> (<i>AmBisome</i>) for cryptococcal meningitis: a retrospective study in HIV-infected patients. <i>Therapeutic Advances in Infectious Disease</i> , 2018, 5, 77-81.	1.8	7
46	Minimum Inhibitory Concentration Distribution of Fluconazole Against <i>Cryptococcus</i> Species and the Fluconazole Exposure Prediction Model. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	17
47	Shortâ€“course amphotericin B in addition to sertraline and fluconazole for treatment of HIVâ€“associated cryptococcal meningitis in rural Tanzania. <i>Mycoses</i> , 2019, 62, 1127-1132.	4.0	13
48	Cisplatin protects mice from challenge of <i>Cryptococcus neoformans</i> by targeting the Prp8 intein. <i>Emerging Microbes and Infections</i> , 2019, 8, 895-908.	6.5	20
49	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019, 69, 588-595.	5.8	18
50	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	1.9	6
51	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	5.8	13
52	Lactoferrin-Derived Peptide Lactofungin Is Potently Synergistic with Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
53	What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 963.	3.5	4
54	<p><i>Cryptococcus neoformans/gattii</i> Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 673-681.	2.7	7

#	ARTICLE	IF	CITATIONS
55	Small-molecule inhibitors for the Prp8 intein as antifungal agents. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
56	Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa. BMC Health Services Research, 2021, 21, 305.	2.2	12
57	Effective inhibition of Cbf-14 against Cryptococcus neoformans infection in mice and its related anti-inflammatory activity. Fungal Genetics and Biology, 2018, 110, 38-47.	2.1	3
58	Comparison of Cryptococcal Antigenemia between Antiretroviral Naïve and Antiretroviral Experienced HIV Positive Patients at Two Hospitals in Ethiopia. PLoS ONE, 2013, 8, e75585.	2.5	44
59	Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS ONE, 2016, 11, e0158986.	2.5	31
60	Cryptococcosis and HIV. , 2016, , 1-12.		0
61	Cryptococcosis and HIV. , 2018, , 397-409.		0
62	Pharmacoeconomics. , 2020, , 1-135.		0
63	A case of an AIDS patient with infection. Pan African Medical Journal, 2020, 36, 88.	0.8	0
64	Reimagining the future of African brain health: Perspectives for basic research on the pathogenesis of cryptococcal meningitis. Brain, Behavior, & Immunity - Health, 2021, 18, 100388.	2.5	3
65	Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries. Medical Mycology, 2022, 60, .	0.7	1
68	Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets. Pathogens, 2022, 11, 569.	2.8	2
70	Therapeutic Lumbar Punctures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?. Open Forum Infectious Diseases, 2022, 9, .	0.9	6
71	Analysis of the efficacy and related factors of ventriculoperitoneal shunt for AIDS with cryptococcal meningitis. Frontiers in Surgery, 0, 9, .	1.4	2
72	The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infectious Diseases, The, 2022, 22, 1748-1755.	9.1	164
73	Pharmacoeconomics. , 2022, , 101-234.		0
74	Criptococosis Multirresistente asociada con hipertensi3n intracraneana idiop3tica. Revisi3n de la literatura y reporte de un caso. Journal of Neuroscience and Public Health, 2023, 3, 319-330.	0.0	0
75	Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV disease in nine countries. Journal of the International AIDS Society, 2023, 26, .	3.0	2

#	ARTICLE	IF	CITATIONS
77	Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis <i>in vivo</i> . Antimicrobial Agents and Chemotherapy, 2023, 67, .	3.2	0
78	Cryptococcal meningitis. Nature Reviews Disease Primers, 2023, 9, .	30.5	2
79	Cryptococcal Meningoencephalitis Infection in Children and Hearing Loss. , 2023, , 919-926.		0